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Background: Array comparative genomic hybridization (CGH) is a powerful tool for detecting unbalanced
chromosomal alterations. To validate the usefulness of array CGH in newborn screening, we examined 20,126
unselected infants. In addition, the number of newborns analyzed with array CGH is the largest one ever reported.
Findings: A total of 20,126 unselected newborns were investigated with array CGH and cytogenetic analyses.
The analyses revealed 87 cases with chromosome abnormalities. Of these, 53 cases had significant chromosome
aneuploidies, including trisomy 13, trisomy 21, 47,XXY or 45,X, and the other 34 cases presented partial
chromosomal deletions or duplications.
Conclusions: In this study, we show that array CGH is an appropriate tool for the screening of chromosomal
abnormalities in newborns, especially for the infants without distinct clinical features.
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Array Comparative Genomic Hybridization (CGH) was
developed as a screening strategy for detecting genome-
wide DNA copy number changes and many groups have
studied the clinical applications of array CGH in both
prenatal and postnatal settings [1-5]. Chromosomal abnor-
malities are a major cause of congenital and developmen-
tal abnormalities in human genetic diseases, associated
with dysmorphic features, mental retardation and develop-
mental delays, as well as multiple congenital anomalies.
The most common chromosome abnormalities in new-
borns are trisomy 21 and sex chromosome abnormalities.
The early diagnosis of these chromosomal disorders is
very important to achieve optimal management and treat-
ment [6,7]. The International Standard Cytogenomic
Array (ISCA) Consortium published a consensus state-
ment on the use of chromosomal microarray as a first tier
diagnostic test in the evaluation of individuals with devel-
opmental delays and/or congenital anomalies [4]. Our
group successfully developed and validated a bacterial* Correspondence: ceo@mgmed.com
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reproduction in any medium, provided the orartificial chromosome (BAC)-based array CGH analysis
platform including analysis software [8].
In this study, we investigated 20,126 unselected new-
borns with array CGH and identified 87 abnormal cases.
Results
Whole-genome array CGH analysis was performed as a
first line test to screen for genomic imbalances in 20,126
unselected newborn infants (Table 1). We simultan-
eously performed FISH and a G-banding analysis to con-
firm abnormal results of array CGH data. Of 20,126
neonatal cases, 0.43% (87/20,126) had DNA copy num-
ber variations: 53 cases of aneuploidy, 23 deletions, and
11 duplications (Table 2). Among the 53 aneuploidies, 18
cases were autosomal aneuploidies (18/20,126; 0.08%), and
35 cases involved sex chromosomes (35/20,126; 0.17%).
The most frequent chromosomal abnormality was trisomy
21, and 47,XXY was the next most common aneuploidy.
Gains or losses associated with chromosomal deletion
(microdeletion) or duplication (microduplication) were ob-
served in 34 cases. For examples, 3q29 microdeletion
syndrome (arr[hg19] 3q29(196,412,227-197,102,739) × 1),
Cri-du-chat syndrome (arr[hg19] 5p15.2p15.3(9,458,494-
9,803,306) × 1), Soto’s syndrome (arr[hg19] 5q35.2q35.3. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Summary of array CGH analysis
Cases with abnormal array CGH analysisa Total
(N)
Detection
rate (%)Aneuploidy (N) Deletion (N) Duplication (N)
Neonatal casesb
(N = 20126) 53 23 11 87 0.43
a array CGH analysis results confirmed by Karyotyping and FISH analyses.
bAll neonatal cases, collected < 0.5 year of age, between 2010–2012.
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syndrome (arr[hg19] 15q11.2(24,055,918-27,026,553) × 1),
DiGeorge syndrome (arr[hg19] 22q11.2(19,030,620-19,
861,970) × 1), Steroid sulfatase deficiency (arr[hg19]
Xp22.31(7,078,532-7,676,445) × 1), Hereditary neuropathy
with liability to pressure palsies (arr[hg19] 17p11.2
(15,067,223-15,225,580) × 1), and Charcot-Marie-Tooth Dis-
ease type 1 (arr[hg19] 17p11.2(15,067,223-15,225,580) × 3).
We also identified 15q11.2q12 interstitial duplication
which is validated by karyotyping and FISH as 46,XY.ishTable 2 Summary of abnormal cases
Array CGH analysis Cytogenetic analyses a
Aneuploidy
Duplication of whole chr.13 Trisomy 13
Duplication of whole chr.21 Trisomy 21
Duplication of whole chr.X 47,XXY
Duplication of whole chr.Y 47,XYY
Duplication of whole chr.X 47,XXX
Deletion of whole chr.X 45,X
Deletion of whole chr.X mos 45,X[28]/ 46,X,i(X)(p22.3→ q22
Deletion/ Microdeletion
Deletion of 0.6 Mb at 3q29 46,XY.ish del(3)(q29)(PAK2-)
Deletion of 0.3 Mb at 5p15.2p15.3 46,XX.ish del(5)(p15.2p15.3)(D5S727
Deletion of 0.3 Mb at 5q35.2q35.3 46,XY.ish del(5)(q35.2q35.3)(NSD1-)
Deletion of 3 Mb at 15q11.2 46,XX.ish del(15)(q11.2q11.2)(SNRPN
Deletion of 0.3 Mb at 17p11.2 46,XY.ish del(17)(p11.2p11.2)(PMP22
Deletion of 0.3 Mb at 17p11.2 46,XX.ish del(17)(p11.2p11.2)(PMP22
Deletion of 0.8 Mb at 22q11.2 46,XY.ish del(22)(q11.2q11.2)(TBX1-)
Deletion of 0.6 Mb at Xp22.31 46,XY.ish del(X)(p22.31p22.31)(STS-)
Deletion of 53 Mb at Xp11.2pter/ 46,X,i(X)(q10)
Duplication of 94 Mb at Xq10qter
Deletion of 55 Mb at Xq21qter 46,X,del(X)(q21qter)
Duplication/ Microduplication
Duplication of 0.3 Mb at15q11.2 46,XY.ish dup(15)(q11.2q11.2)(SNRP
Duplication of 0.2 Mb at17p11.2 46,XY.ish dup(17)(p11.2p11.2)(PMP2
Duplication of 0.8 Mb at22q11.2 46,XY.ish dup(22)(q11.2q11.2)(COMT
Duplication of 0.8 Mb at22q11.2 46,XX.ish dup(22)(q11.2q11.2)(COMT
Small supernumerary marker chr
Duplication of 2 Mb at 15q11.2q13 mos 47,XX,+inv dup(15)(q11.2q13)[
HNPP, Hereditary neuropathy with liability to pressure palsies; CMT1A, Charcot-Mar
a Karyotyping and FISH analyses.dup(15)(q11.2q12)(SNRPN+). And Inverted duplication
15q case involving mosaicism and a small supernumer-
ary marker chromosome (sSMC) were also found. We
identified various microdeletion or duplication cases
and the molecular cytogenetic results are shown in
Figure 1.
Discussion
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Figure 1 Examples of Array CGH and FISH results for 3q29 microdeletion case (A, C) and 17p11.2 duplication case (B, D). (A) The array
CGH result for chromosome 3. Arrow indicates deletion of the 3q29 region including the PAK2 and DLG1 genes. (B) The array CGH result for
chromosome 17. Arrow indicates duplication of the CMT1A region (17p11.2). (C) FISH result analyzed with a 3q29 region specific probe; arrow
indicates a deletion of 3q29 region in chromosome 3. (D) FISH with 17p11.2 region specific probe; arrows indicate a duplication of 17p11.2
region in an interphase cell.
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specific copy-number imbalance. We have developed an
array CGH analysis system for constitutional genetic diag-
nosis and have evaluated the suitability of our system for
molecular diagnosis. Our array CGH chip consists of
1,440 non-overlapping bacterial artificial chromosome
(BAC) clones, which were selected from 96,768 BAC
clones constructed by the Korean Genome Project and
validated by end-sequencing and FISH [8,9]. Therefore,
the abnormal array CGH results were able to be con-
firmed by FISH.
Several studies of unbalanced chromosomal abnor-
malities in newborns have reported prevalence rates of
17 ~ 31/10,000 live births [10-12]. Recently, Wellesley
et al. reported that the overall frequency of unbal-
anced chromosome abnormalities was 0.43% (43.8/
10,000) [7]. Of these, 0.36% was significant chromo-
some aneuploidies (T21, T18, T13, sex chromosome
trisomies, and 45,X) and 0.07% was rare chromosome
abnormalities (triploidy, other trisomies, marker chro-
mosomes, unbalanced translocations, deletions, andduplications). Similarly, we observed abnormalities in
0.43% of 20,126 unselected newborn infants (Table 1).
Of these, 0.26% (53/20,126) was characterized as signifi-
cant chromosome aneuploidy. Regarding rare chromo-
some abnormalities, we found 0.17% of frequency which
is much higher than 0.07% reported by Wellesley et al.
The difference is due to different methods to detect
chromosome abnormalities.
Trisomy 21 and sex chromosome aneuploidy (XXY,
XXX, XYY and 45,X) were the most frequent abnor-
malities (Table 2). In addition to the high frequency of
diseases associated with aneuploidies, detecting chromo-
somal abnormalities at an early age is very important for
the optimal management and treatment of the affected
newborns. For example, patients with Turner syndrome
(TS) can be treated with growth hormones if they are di-
agnosed early in life. However, many girls with TS are not
diagnosed until after 10 years of age, thus resulting in de-
layed evaluation and treatment [13]. Although Klinefelter
syndrome is mainly diagnosed in pre-pubertal males, early
identification and anticipatory guidance are extremely
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makes it easier to achieve the goals of treatment, particu-
larly controlling the symptoms and managing the resulting
medical conditions [15].
The chromosome deletions and duplications identified
in the remaining 34 abnormal cases are associated with
many clinical indications, such as developmental delays
and mental retardation. The 22q11.2 deletion syndrome,
also known as DiGeorge syndrome or velocardiofacial
syndrome, is a genetic disorder with multisystemic ma-
nifestations, including congenital cardiac abnormalities,
palatal anomalies, T-cell immunodeficiency, craniofacial
features, cognitive deficits and schizophrenia [16,17]. The
early diagnosis of and early intervention for psychiatric ill-
nesses improve the long-term prognosis in individuals
with schizophrenia and bipolar disorder [18]. Other treat-
ments can usually correct critical problems, such as heart
defects or low calcium levels [19].
The 5p15 deletion syndrome, known as “cat cry” or
Cri du Chat syndrome, has clinical features such as low
weight, microcephaly, round face, large nasal bridge,
hypertelorism, epicanthal folds, downward-slanting pal-
pebral fissures, down-turned corners of the mouth, ab-
normal dermatoglyphics, and a characteristic sounding
cry in infancy [20]. We also identified 15q11.2 duplica-
tions. The symptoms associated with these duplications
appear to range from minor (apparently normal) to highly
severe mental retardation, growth retardation, and autism
[21]. The early recognition of Charcot-Marie-Tooth type
1, which is caused by a 17p11.2 duplication, can prevent
life-threatening vincristine neurotoxicity [22].
Chromosomal disorders with developmental delays or
mental retardation may not be recognized until a certain
developmental stage. Some patients who have chromo-
somal aberrations, such as 47,XXY or 45,X, do not ex-
hibit clinical features until after a certain year of age.
Although there are no cures for chromosomal disorders,
many patients without distinct clinical features can be
effectively managed and treated in the early stages of de-
velopment by early diagnosis with array CGH.
In this study, we showed that our newly developed array
CGH platform is very useful for clinical application in
newborns, especially for the infants without distinct clin-
ical features. In addition, the number of newborns ana-
lyzed with array CGH is the largest one ever reported.
Materials and methods
Patient samples
We analyzed samples obtained from 20,126 unselected
neonates who had been referred to MGMED laborator-
ies for array CGH analysis between January 2010 and
December 2012. A total of 20,126 unselected neonatal
samples (16,850 peripheral blood and 3,276 cord blood)
were collected for chromosome abnormality screening.All samples were prepared for experiments using previ-
ously described methods [8]. All patient materials were
obtained and evaluated with informed patient consent
and with the approval of the Ethics Committees of the
MGMED clinical center.
Array CGH and cytogenetic analyses
Approximately 100 ~ 200 ng of DNA was used for the
array CGH experiments, as described, with slight modifi-
cations [2]. The slides contained 1440 human BAC clones
including specific loci for more than 50 chromosomal
disorders. Briefly, DNA was labeled with Cy-3 and Cy-5
dCTP by a random priming method for 3 h. The labeled
DNA was purified, dissolved in hybridization buffer and
hybridized overnight. The slides were washed several times
and dried. Slide images were acquired with a GenePix4000B
dual-laser scanner (Axon Instruments, Union City, CA)
and analyzed with MacViewer software. Chromosome ana-
lysis was performed according to standard methods using
cultured cells from peripheral blood samples obtained
from the patient. FISH studies on interphase or metaphase
spreads with specific probes were performed as described
[8]. Cytogenetic analyses were described according to the
conventions of the International System for Human
Cytogenetic Nomenclature (ISCN, 2013).
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